Consequences Of Aneuploidy As Cause, Not Effect, Of The Cancer Genome
This article was originally published in Start Up
Geneticists from Harvard Medical School have now shown that aneuploidy, or the occurrence of an extra or missing number of chromosomes within a cell, actually drives tumors, rather than being a byproduct of tumor formation, giving support to the development of aneuploidy-directed cancer treatment strategies.
You may also be interested in...
A half decade of large-scale cancer genome sequencing has identified only one new and relatively common druggable oncogene target. But the genes that cause out-of-control proliferation also create problems for the cancer cells, which may then need to hijack normal cellular functions to help them survive. A research team used genetic screening to find such a dependency and showed that inhibiting the process could improve treatment.
A recent report shows that some cancer cells may be more sensitive to chemotherapy because their mitochondria are primed to undergo programmed cell death. An assay that identifies the start of the process could help optimize the use of traditional chemo. And novel agents not potent enough to be used against tumors on their own could selectively prime tumors in this way as part of combination therapy.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.